Atrion (NASDAQ: ATRI) and Alliqua Biomedical (NASDAQ:ALQA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Institutional and Insider Ownership
59.0% of Atrion shares are held by institutional investors. 23.1% of Atrion shares are held by insiders. Comparatively, 15.8% of Alliqua Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.8%. Alliqua Biomedical does not pay a dividend. Atrion pays out 26.6% of its earnings in the form of a dividend. Alliqua Biomedical has raised its dividend for 15 consecutive years.
Earnings & Valuation
This table compares Atrion and Alliqua Biomedical’s gross revenue, earnings per share and valuation.
||Earnings Per Share
Atrion has higher revenue and earnings than Alliqua Biomedical. Alliqua Biomedical is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations and price targets for Atrion and Alliqua Biomedical, as provided by MarketBeat.com.
||Strong Buy Ratings
Alliqua Biomedical has a consensus target price of $10.10, indicating a potential upside of 397.22%. Given Alliqua Biomedical’s higher possible upside, analysts plainly believe Alliqua Biomedical is more favorable than Atrion.
This table compares Atrion and Alliqua Biomedical’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility & Risk
Atrion has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Alliqua Biomedical has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Atrion beats Alliqua Biomedical on 11 of the 15 factors compared between the two stocks.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.
About Alliqua Biomedical
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.